Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.01 par value per share
-
Shares outstanding
-
81.1M
-
Number of holders
-
165
-
Total 13F shares, excl. options
-
86.9M
-
Shares change
-
+17.3M
-
Total reported value, excl. options
-
$1.98B
-
Value change
-
+$415M
-
Put/Call ratio
-
0.76
-
Number of buys
-
106
-
Number of sells
-
-56
-
Price
-
$22.75
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q3 2024
193 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share as of Q3 2024.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) has 165 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.9M shares
.
Largest 10 shareholders include FMR LLC (11.2M shares), BlackRock, Inc. (4.8M shares), VANGUARD GROUP INC (4.42M shares), VR Adviser, LLC (3.88M shares), Deep Track Capital, LP (3.75M shares), Fairmount Funds Management LLC (3.45M shares), Paradigm Biocapital Advisors LP (2.9M shares), PERCEPTIVE ADVISORS LLC (2.81M shares), COMMODORE CAPITAL LP (2.55M shares), and Kynam Capital Management, LP (2.51M shares).
This table shows the top 165 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.